Meetings
Conference abstracts
81 public abstracts from 2021 to 2026. Findings are the abstract’s own wording. Level 1 items, where ctDNA or MRD assigned treatment or surveillance, have a coral bar. Slide and poster links, when added, may require an ASCO or ESMO member login.
2 abstracts
- Level 3neutralAACR Annual Meeting 2026
Abstract 3845: Enhancing MRD detection through an ultrasensitive ctDNA test: Insights from real-world clinical data
Pyke, Rachel Marty · Abstract 3845 · more than 5,000 patients across 15 cancer types, as stated in the abstract (a single exact n is not given)
NeXT Personal Dx (Personalis), bespoke panel of up to about 1,800 variants
Median limit of detection across timepoints was 1.90 PPM (IQR 1.53-2.70) at a median cfDNA input of 12 ng. 45.3% of tests were ctDNA-positive. 40.2% of detections were below 100 PPM, and 14.7% of all detections were below 10 PPM. Among patients who became sustainably positive after a negative timepoint, 49% had a first MRD-positive result below 10 PPM. Two case examples (NSCLC and colorectal cancer) describe low-PPM detections that preceded imaging-confirmed recurrence. This is a real-world analytical and descriptive series, not a prospective outcomes trial.
- Trial in progressESMO Congress 2023
GUIDE.MRD: A consortium guiding multimodal therapies against minimal residual disease by liquid biopsy and ctDNA implementation in clinical practice
Klaus Pantel · Abstract 237TiP · Poster / trial-in-progress · GUIDE.MRD
Trial in progress
PosterPoster PDF. An ASCO or ESMO member login may be required.